Response to Office Action dated October 5, 2009

Atty Docket: 102790-211

Page 2

## II. CLAIMS

In the Claims:

1.(Currently Amended) A recombinant cellular system, comprising an <u>isolated</u> animal host cell, comprising the following recombinant proteins:

- a recombinant, specific G protein-coupled receptor,
- a recombinant CNGA2 Ca2+ permeable channel and
- a substance selected from the group consisting of connexins, a cyclase that is harmonised with the specific G protein-coupled receptor and a recombinant G-protein that is harmonised with the specific G protein-coupled receptor,

where the recombinant specific G protein-coupled receptor, is selected from the group consisting of pheromone receptors and the olfactory receptors, type A guanylyl-cyclases, and type G guanylyl-cyclases.

- 2. (Withdrawn) The recombinant cellular system according to claim 1, where the substance is a recombinant protein selected from the group of connexins.
- 3.(Withdrawn) The recombinant cellular system according to claim 1, wherein the recombinant specific G protein-coupled receptor is selected from type A guanylyl-cyclases and type G guanylyl-cyclases.
- 4.(Withdrawn) The recombinant cellular system according to claim 1 where the substance is a cyclase that is harmonised with the specific G protein-coupled receptor.
- 5. (Currently Amended) The recombinant cellular system according to claim 1, wherein the recombinant, specific G protein-coupled receptor is selected from: pheromone receptors,

Response to Office Action dated October 5, 2009

Atty Docket: 102790-211

Page 3

hormone receptors and the olfactory receptors.

- 6.(Withdrawn) The recombinant cellular system according to claim 1 where the substance is a recombinant G-protein that is harmonised with the specific G protein-coupled receptor.
- 7. (Previously Presented) The recombinant cellular system according to claim 1 wherein the animal host cell is selected from murine cell lines and human cell lines.
- 8.(Currently Amended) The recombinant cellular system according to claim 1, wherein the cellular system comprises a potential recombinant, specific G protein-coupled receptor.
- 9.(Previously Presented) The recombinant cellular system according to claim 7, selected from the group of cellular systems comprising: HeLaCx43/CNGA2/01fr49; HeLa-Cx43/CNGA2/G-alpha-olf; HeLa-Cx43/CNGA2/G-alpha-olf/01fr 49; HeLa-Cx43/CNGA2/G-alpha-olf/01fr 41; HeLa-Cx43/CNGA2/G-alpha-olf/01fr 6 and HeLa-Cx43/CNGA2/G-alpha-olf/0R1A1.
- 10.(Previously Presented) The recombinant cellular system according to claim 1, wherein the recombinant proteins are present stably.
- 11.(Previously Presented) The recombinant cellular system HeLa- Cx43/CNGA2/G-alpha-olf, as deposited on April 20, 2004 at the DSMZ Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH in Mascheroder Weg lb, D38124 Braunschweig with the deposit number DSM ACC2649.
- 12. (Withdrawn) A method for producing a recombinant cellular system, comprising the steps of:
  - providing of an animal host cell,
  - introducing a recombinant specific G protein-coupled

Response to Office Action dated October 5, 2009

Atty Docket: 102790-211

Page 4

receptor or a potential recombinant specific G protein-coupled receptor, and

- introducing the recombinant CNGA2 Ca2+ permeable channel.
- 13.(Withdrawn) The method according to claim 12, further comprising the step of:
- introducing a recombinant protein from the group of the connexins.
- 14.(Withdrawn) The method according to claim 12, further comprising the step of:
- introducing a cyclase that is harmonised with the specific G protein-coupled receptor.
- 15.(Withdrawn) The method according to claim 12 further comprising the step of:
- introducing of a recombinant G-protein that is harmonised with the specific G protein-coupled receptor.
- 16.(Withdrawn) The method according to claim 12, wherein the introducing method step is selected from: (Ca2+-phosphate-) transfection, lipofection or electroporation,

optionally followed by the step of integration into the genome with the aid of a recombinase or antibiotic-selection cloning, or the step of transduction.

- 17. (Withdrawn) The method for identifying receptor activating substances, comprising the method steps of providing a recombinant cellular system according to claim 1,
- contacting the cellular system with a potential G protein-coupled receptor activating substance, and
  - measuring the activation or inhibition of the Ca2+ influx

Response to Office Action dated October 5, 2009

Atty Docket: 102790-211

Page 5

into the cellular system cell.

- 18.(Withdrawn) The method according to claim 17, wherein the potential G protein-coupled receptor inducing substance is selected from odorants, pheromones, and hormones.
- 19.(Withdrawn) The method according to claim 17, wherein the measuring of the Ca2+ influx into the cell includes: loading of the cell with Fura-2-AM or Fluo-4-AM, and measuring the emission-wavelength at 515 nm.
- 20.(Withdrawn) The method according to claim 17, wherein the cellular system is pre-treated with an enhancer.
- 21. (Withdrawn) A method for producing a pharmaceutical composition, comprising the steps of:
  - performing a method according to claim 17, and
- formulating the obtained G protein-coupled receptor inducing substance with auxiliary agents and additives.
- 22.(Withdrawn) A method for identifying of G protein-coupled receptors, comprising the steps of:
- providing a recombinant cellular system according to claim 8,
- contacting of the cellular system with a receptoractivating substance or presumably receptor-activating substance, and
- measuring the activation or inhibition of the Ca2+ influx into the cell.
- 23. (Withdrawn) The method according to claim 17, wherein the method is performed in a high-throughput-environment.
  - 24. (Cancelled)

Response to Office Action dated October 5, 2009

Atty Docket: 102790-211

Page 6

## 25. (Cancelled)

- 26.(Previously Presented) The recombinant cellular system of claim 1 where the G protein-coupled receptor is selected from the group consisting of OR1A1, OR1A2, Olfr43, Olfr49, MOR261-10, MOR267-1, LOC31758, Olfr41 and Olf6 and the connexin is selected from the group consisting of Cx43 and Cx26.
- 27. (Previously Presented) The recombinant cellular system of claim 9 where the cellular system is HeLa-Cx43/CNGA2/G-alpha-olf.